Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?
Bladder cancer care is shifting toward continuous reassessment rather than fixed treatment plans, better catching changes over time.
This PubMed record reports: Current classifications remain necessary but insufficient alone; treatment selection increasingly requires a dynamic, multi-axial framework reassessed at defined checkpoints rather than fixed at diagnosis. The finding is retained for rapid triage and requires downstream evidence review before clinical interpretation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The French journal of urology
Why it surfaced
Retained because its randomized controlled trial evidence is relevant to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; scoring is conservative for the available metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.